Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 127

1.

Blind Biobanking of the Prostatectomy Specimen: Critical Evaluation of the Existing Techniques and Development of the New 4-Level Tissue Extraction Model With High Sampling Efficacy.

Tolkach Y, Eminaga O, Wötzel F, Huss S, Bettendorf O, Eltze E, Abbas M, Imkamp F, Semjonow A.

Prostate. 2016 Nov 16. doi: 10.1002/pros.23278. [Epub ahead of print]

PMID:
27862105
2.

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer.

Schlack K, Krabbe LM, Fobker M, Schrader AJ, Semjonow A, Boegemann M.

Int J Mol Sci. 2016 Sep 9;17(9). pii: E1520. doi: 10.3390/ijms17091520.

3.

Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.

Boegemann M, Schlack K, Fischer AK, Gerß J, Steinestel J, Semjonow A, Schrader AJ, Krabbe LM.

PLoS One. 2016 Sep 1;11(9):e0161959. doi: 10.1371/journal.pone.0161959.

4.

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.

Mikah P, Krabbe LM, Eminaga O, Herrmann E, Papavassilis P, Hinkelammert R, Semjonow A, Schrader AJ, Boegemann M.

BMC Cancer. 2016 Mar 14;16:214. doi: 10.1186/s12885-016-2260-y.

5.

Correlation of Intraprostatic Tumor Extent with ⁶⁸Ga-PSMA Distribution in Patients with Prostate Cancer.

Rahbar K, Weckesser M, Huss S, Semjonow A, Breyholz HJ, Schrader AJ, Schäfers M, Bögemann M.

J Nucl Med. 2016 Apr;57(4):563-7. doi: 10.2967/jnumed.115.169243.

PMID:
26769858
6.

Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.

Bokhorst LP, Lepistö I, Kakehi Y, Bangma CH, Pickles T, Valdagni R, Alberts AR, Semjonow A, Strölin P, Montesino MF, Berge V, Roobol MJ, Rannikko A.

BJU Int. 2016 Sep;118(3):366-71. doi: 10.1111/bju.13410.

PMID:
26765682
7.

Analysis of topographical distribution of prostate cancer and related pathological findings in prostatectomy specimens using cMDX document architecture.

Eminaga O, Semjonow A, Eltze E, Bettendorf O, Schultheis A, Warnecke-Eberz U, Akbarov I, Wille S, Engelmann U.

J Biomed Inform. 2016 Feb;59:240-7. doi: 10.1016/j.jbi.2015.12.009.

PMID:
26707451
8.

Preoperative Serum Prostate-Specific Antigen Levels Vary According to the Topographical Distribution of Prostate Cancer in Prostatectomy Specimens.

Eminaga O, Hinkelammert R, Abbas M, Wötzel F, Eltze E, Bettendorf O, Boegemann M, Semjonow A.

Urology. 2015 Oct;86(4):798-804. doi: 10.1016/j.urology.2015.07.029.

PMID:
26255036
10.

Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2015 Feb 11;16(2):3856-69. doi: 10.3390/ijms16023856.

11.

Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.

Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94. doi: 10.1016/j.ijrobp.2014.09.039.

PMID:
25445556
12.

Preoperative prostate-specific antigen isoform p2PSA ≤ 22.5 pg/ml predicts advanced prostate cancer in patients undergoing radical prostatectomy.

Eminaga O, Bögemann M, Breil B, Titze U, Wötzel F, Eltze E, Bettendorf O, Semjonow A.

Urol Oncol. 2014 Nov;32(8):1317-26. doi: 10.1016/j.urolonc.2014.04.018.

PMID:
24893699
13.

The need for harmonized structured documentation and chances of secondary use - results of a systematic analysis with automated form comparison for prostate and breast cancer.

Krumm R, Semjonow A, Tio J, Duhme H, Bürkle T, Haier J, Dugas M, Breil B.

J Biomed Inform. 2014 Oct;51:86-99. doi: 10.1016/j.jbi.2014.04.008.

14.

Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Stöckle M, Rübe C, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K.

Eur Urol. 2014 Aug;66(2):243-50. doi: 10.1016/j.eururo.2014.03.011.

PMID:
24680359
15.

Prostate cancers detected on repeat prostate biopsies show spatial distributions that differ from those detected on the initial biopsies.

Eminaga O, Hinkelammert R, Abbas M, Titze U, Eltze E, Bettendorf O, Wötzel F, Bögemann M, Semjonow A.

BJU Int. 2015 Jul;116(1):57-64. doi: 10.1111/bju.12691.

16.

Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study.

Westermann AM, Schmidt D, Holdenrieder S, Moritz R, Semjonow A, Schmidt M, Kristiansen G, Müller SC, Ellinger J.

Anticancer Res. 2014 Feb;34(2):665-9.

PMID:
24510997
17.

Tumor percentage but not number of tumor foci predicts disease-free survival after radical prostatectomy especially in high-risk patients.

Hinkelammert R, Eminaga O, Bettendorf O, Eltze E, Abbas M, Hertle L, Semjonow A.

Urol Oncol. 2014 May;32(4):403-12. doi: 10.1016/j.urolonc.2013.10.001.

PMID:
24332639
18.

An electronic specimen collection protocol schema (eSCPS). Document architecture for specimen management and the exchange of specimen collection protocols between biobanking information systems.

Eminaga O, Semjonow A, Oezguer E, Herden J, Akbarov I, Tok A, Engelmann U, Wille S.

Methods Inf Med. 2014;53(1):29-38. doi: 10.3414/ME13-01-0035.

PMID:
24317441
19.

Linkage of data from diverse data sources (LDS): a data combination model provides clinical data of corresponding specimens in biobanking information system.

Eminaga O, Özgür E, Semjonow A, Herden J, Akbarov I, Tok A, Engelmann U, Wille S.

J Med Syst. 2013 Oct;37(5):9975. doi: 10.1007/s10916-013-9975-y.

PMID:
24022214
20.

Genome-wide investigation of multifocal and unifocal prostate cancer-are they genetically different?

Ibeawuchi C, Schmidt H, Voss R, Titze U, Abbas M, Neumann J, Eltze E, Hoogland AM, Jenster G, Brandt B, Semjonow A.

Int J Mol Sci. 2013 Jun 3;14(6):11816-29. doi: 10.3390/ijms140611816.

Items per page

Supplemental Content

Loading ...
Support Center